Analysts Anticipate Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Will Announce Earnings of -$0.91 Per Share

Wall Street brokerages forecast that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will report earnings per share of ($0.91) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals’ earnings. The highest EPS estimate is ($0.74) and the lowest is ($1.06). Rhythm Pharmaceuticals posted earnings per share of ($0.74) in the same quarter last year, which would indicate a negative year over year growth rate of 23%. The company is scheduled to report its next quarterly earnings report on Friday, March 13th.

According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.19) to ($3.82). For the next financial year, analysts forecast that the business will post earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks’ EPS calculations are an average based on a survey of research firms that follow Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Friday, November 1st. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.02.

RYTM has been the topic of a number of research analyst reports. BidaskClub raised Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 22nd. Zacks Investment Research upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday. Cowen reissued a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a research report on Wednesday, September 25th. Finally, LADENBURG THALM/SH SH restated a “buy” rating and set a $43.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $36.50.

Shares of RYTM stock traded up $1.35 during mid-day trading on Friday, hitting $23.87. The company’s stock had a trading volume of 494,677 shares, compared to its average volume of 183,258. Rhythm Pharmaceuticals has a 52-week low of $18.00 and a 52-week high of $31.94. The business has a 50-day moving average price of $21.89 and a 200 day moving average price of $22.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.78 and a current ratio of 6.78. The stock has a market cap of $996.90 million, a price-to-earnings ratio of -9.99 and a beta of 0.66.

In other Rhythm Pharmaceuticals news, Director Todd Foley sold 25,366 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $22.03, for a total value of $558,812.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 444,075 shares of company stock valued at $9,935,520. 4.45% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the business. Marshall Wace North America L.P. bought a new stake in shares of Rhythm Pharmaceuticals during the 1st quarter valued at about $33,000. Point72 Hong Kong Ltd purchased a new stake in shares of Rhythm Pharmaceuticals during the 2nd quarter valued at about $31,000. Rice Hall James & Associates LLC lifted its stake in shares of Rhythm Pharmaceuticals by 2.5% in the 3rd quarter. Rice Hall James & Associates LLC now owns 64,804 shares of the company’s stock worth $1,399,000 after purchasing an additional 1,587 shares during the period. Bank of Montreal Can boosted its holdings in shares of Rhythm Pharmaceuticals by 194,200.0% in the second quarter. Bank of Montreal Can now owns 1,943 shares of the company’s stock worth $43,000 after buying an additional 1,942 shares during the last quarter. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 26.1% in the second quarter. Virtus ETF Advisers LLC now owns 11,938 shares of the company’s stock worth $263,000 after buying an additional 2,470 shares during the last quarter. 78.13% of the stock is currently owned by institutional investors.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Read More: Percentage Gainers

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.